New Preclinical and Clinical Approaches to Mesothelioma

Launched by MARCO EMILIO BIANCHI · Jul 31, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how two specific factors, HMGB1 and CXCR4, affect mesothelioma, a type of cancer often linked to asbestos exposure. Researchers believe that by targeting these factors, they can slow down cancer growth and improve the body’s ability to fight the disease. The trial involves collaboration between two leading cancer research centers and aims to develop new treatments that may help patients with this serious condition.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of pleural mesothelioma, meaning the cancer is located in the lining of the lungs. Candidates should also be considered for surgery. There is also a control group for patients with other confirmed diseases who meet similar age and surgical criteria. Participants can expect to undergo evaluations related to their condition and may receive new therapies under study. It’s important to note that candidates will need to provide informed consent and should not be pregnant or lack necessary biopsy materials.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients with Mesothelioma:
• • Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma.
• • Candidates for surgical intervention.
• • Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women.
• • Capacity to comprehend the study nature and provide autonomously informed consent.
• Control Group patients:
• • Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious).
• • Candidates for surgical intervention.
• • Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women.
• • Ability to understand the study nature and provide autonomously informed consent.
• • If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study.
• Exclusion Criteria:
• • Lack of biopsy material.
• • pregnancy.
• • Unwillingness to sign the Informed Consent.